港股早評:恒指微幅低開0.05%,核電股大升,比亞迪開升近2%
隔夜美股三大指數收升,熱門中概股多數上升。昨日走強的港股三大指數小幅低開,恒指跌0.05%,國指跌0.08%,恒生科技指數跌0.34%。盤面上,大型科技股多數下跌,美團跌1.39%,京東跌1%,網易、阿里巴巴、快手飄綠,騰訊升近1%,小米升0.56%;核電股大幅上升,中廣核礦業大升超14%表現搶眼,中核國際升6.6%,汽車股、半導體股、電信股多數上升,比亞迪股份升近2%。另一方面,生物科技股普遍下跌,博安生物跌5.6%,基石藥業、康希諾生物、藥明康德走低;保險股、體育用品股普跌,其中,中國財險跌近2%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.